Navigation Links
Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Date:12/4/2007

CAMBRIDGE, Mass., Dec. 4 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announces the acceptance of four abstracts for presentation at the American Society for Clinical Pharmacology and Therapeutics annual meeting to be held April 2-5, 2008. The Society is the largest scientific and professional organization serving the discipline of clinical pharmacology.

These abstracts address the basis for adverse event outcomes and other key findings in previous surgical studies of Hemopure. Biopure and the collaborating scientists also address the safety and efficacy of both Hemopure and Hemoglobin-based oxygen carriers (HBOCs) in general. The titles, authors and affiliations are as follows:

RISK OF ADVERSE OUTCOME DUE TO ACUTE ANEMIA IN THE ORTHOPEDIC SURGICAL SETTING. L. B. Pearce, A. N. Pitman; Biopure Corporation, Cambridge, MA.

BREAKING THE RULES: MISINTERPRETATION OF DOSE-RESPONSE RELATIONSHIPS IN CLINICAL TRIALS. L. B. Pearce, A. N. Pitman, A. G. Greenburg; Biopure Corporation, Cambridge, MA.

A FLEXIBLE OUTCOME SCORING SYSTEM FOR CLINICAL TRIALS. A. N. Pitman, L. B. Pearce; Biopure Corporation, Cambridge, MA.

APPLICATION OF A UNIQUE SCORING SYSTEM FOR NUMERICAL DETERMINATION OF A BENEFIT RISK RATIO IN CLINICAL TRIALS. L. B. Pearce(1), A. Pitman,(1) A. G. Greenburg,(1) D. A. Freilich,(2) L. Kaplan(3); (1)Biopure Corporation, Cambridge, MA, (2)Naval Medical Research Center, Silver Spring, MD, (3)Yale University School of Medicine, New Haven, CT.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin.

Contact: Tiana Gorham Herb Lanzet (Investors)

Biopure Corporation H.L. Lanzet Inc.

(617) 234-6826 (212) 888-4570

IR@biopure.com lanzet@aol.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
5. Scientists Probe Sepsis Deadly Secrets
6. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
7. Scientists Develop Natural Protection for Stored Foods
8. Scientists detect presence of marburg virus in african fruit bats
9. Scientists Spot Brains Free Will Center
10. Scientists ID Likely Culprit in Popcorn Lung
11. Scientists explain how insulin secreting cells maintain their glucose sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in the ... and along with that; a humdinger of an allergy season. A relief from drought ... increase in misery-causing grass and weed pollen. , “Our patients have been reporting ...
(Date:6/24/2017)... ... 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) ... Erie Convention Center on June 8-10. The weekend consisted of many educational ... and scholarship presentations, and professional networking. , On Friday June 9th, PATS ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better ... ultimately do significant harm to people with all chronic conditions, including mental illnesses, ... leaves in place the Affordable Care Act (ACA) requirement that insurers cover pre-existing ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. Rubinstein ... recently begun offering three new minimally invasive procedures to patients who want a ... downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... essential, and two new videos highlight the importance of correctly using a meat ... Ph.D., who has done extensive research on consumer food safety habits. Dr. Bruhn ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
(Date:5/18/2017)... 2017  Two Bayer U.S. Pharmaceutical leaders received top ... recent 28 th Woman of the Year ... HBA,s longstanding mission of furthering the advancement and impact ... Cindy Powell-Steffen , senior director of brand activation ... Libby Howe , a regional business manager for ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
Breaking Medicine Technology: